Index
985
clinical presentation, 232–233
histamine release, 231
kinin system, 231
Infliximab, 265, 266
Influenza A and respiratory viruses, 126,
127, 130–132
adverse effects, 131
care considerations, 131–132
contraindications and cautions,
130–131
drug–drug interactions, 131
pharmacokinetics, 130
therapeutic actions and
contraindications, 129, 130
Influenza virus vaccines, 274, 280
H1N1 pandemic, 2809t
Inhibin, 596, 602
Inorganic compounds, 5
Insulin, 572–593
adverse effects, 581
care considerations, 582–583
contraindications and cautions, 579,
581
delivery, 580, 581
diabetes mellitus (type I), 584–585
drug–drug interactions, 581–582
name confusion, 579
pharmacokinetics, 579
therapeutic actions and indications,
579, 581
Integrase inhibitor, 126, 136, 141–142
Intellectual functions, 300
Intensives Medicines Monitoring
Programme (IMMP), 65
Interactions, 25, 27–28
drug–drug or drug–alternative therapy,
27–28
drug–food, 28
drug–laboratory test, 28
Interferon alfa-2a, 259, 261
Interferon alfa-2b, 258, 259, 261
Interferon beta-1a, 259, 261
Interferon beta-1b, 259, 261
Interferon gamma-1b, 259, 260, 261
Interferons, 126, 127, 228, 235, 259–261
adverse effects, 261
care considerations, 262–263
contraindications and cautions, 260
drug–drug interactions, 261
pharmacokinetics, 260
therapeutic actions and indications,
259–260
Interleukin-receptor antagonist, 266
adverse effects, 266
care considerations, 267–268
contraindications and cautions, 266
pharmacokinetics, 266
therapeutic actions and indications, 266
Interleukins, 228, 235, 261–262
adverse effects, 262
care considerations, 262–263
contraindications and cautions, 262
pharmacokinetics, 262
therapeutic actions and indications,
261–262
Internet information, 12, 60, 61–62
Interneurons, 385, 386
Interstitial cells, 596, 601, 602
Interstitial cystitis, 819, 827
Intestine, hormones and, 514
Intractable hiccough, 929, 932
Intravenous regional local anaesthesia,
425
Intravenous solutions
dosage calculations, 56–57
Intrinsic pathway, 750, 751, 753
Iodine, 551, 950
Iodine solutions, 552
adverse effects, 561
drug–drug interactions, 561
pharmacokinetics, 560
therapeutic actions and indications,
560
Ion transporters, 17
Ipratropium, 501–503, 864, 867,
873–874, 875
Irbesartan, 665, 669
Irinotecan, 222
Iron
therapeutic effect, 5
toxicity, 784–785
Iron-deficiency anaemia, 774, 776
agents used to treat, 782–787
adverse effects, 783
care considerations, 786–787
contraindications and cautions, 783
drug–drug interactions, 783–784
drug–food interactions, 784
pharmacokinetics, 783
therapeutic actions and indications,
782–783
Iron polymaltose, 782–783
Iron sucrose, 782
Irritable bowel syndrome, 926–927
drugs, 916, 927
Isoflurane, 416, 420, 422, 423
Isoniazid, 91, 118, 119, 120
Isoprenaline, 455, 465–466, 676
Isosorbide dinitrate, 716–718
Isosorbide mononitrate, 716–718
Isotonic solution, 77
Isotretanoin, 953
Isradipine, 665, 671
Itraconazole, 151–154
Ivermectin, 183, 185
J
Jambul, 965
Japanese encephalitis vaccine, 280
Java plum, 471, 965
Jojoba, 965
Journals, 12
Juniper berries, 582, 965
K
Kava, 965
Ketamine, 67, 420, 421
Ketoconazole, 151–154, 157, 951
Ketoprofen, 241, 247
Ketorolac, 241, 247, 957
Ketosis, 572, 576
Ketotifen, 957
Kidneys, 795–800
blood pressure control, 799
blood supply, 796
calcium regulation, 799
chloride regulation, 798
countercurrent mechanism, 797–798
damage, 86
glomerular filtration, 797
hormones and, 514
maintenance of body fluids, 797–799
nephron, 794, 795–797
potassium regulation, 798
regulation of red blood cell production,
799–800
sodium regulation, 797
structure, 795–796
tubular reabsorption, 797
tubular secretion, 797
Kinin system, 228, 231
Kudzu, 966
L
Labels, 11
Labetalol, 469, 470, 472, 676
Lacosamide, 354, 365–367
Lactulose, 919, 920
Lamivudine, 136, 137, 139
Lamotrigine, 154, 344, 345, 354,
365–367
Lanreotide, 525, 528–529
Lansoprazole, 900, 906–907
Lapatinib, 219, 220, 221
Laryngitis, 838
Larynx, 834, 835, 836
Latanoprost, 957
Lavender, 966
Laxatives, 916, 917–922
adults, 917
bulk stimulants, 916, 919, 920
care considerations, 921–922
chemical stimulant, 916, 918–919
children, 917
lubricants, 916, 920–921
older adults, 917
opioid-induced constipation, 405
LDLs (low-density lipoproteins), 729, 732
Ledum tincture, 966
Leflunomide, 253, 254–255
Leishmaniasis, 163, 171
Lepirudin, 757, 766
Leprostatic drugs, 118–121
adverse effects, 119–120
care considerations, 120–121
contraindications and cautions, 119
drug–drug interactions, 120
pharmacokinetics, 119
therapeutic actions and indications,
118–119
Lercanidipine, 666, 671
Letrozole, 212, 214
Leucovorin, 203, 787
Leukocytes, 228, 230
Leukotriene receptor antagonists, 864,
865, 877, 878–880
adverse effects, 878–879
care considerations, 879–880
